(Q37021033)

17 August 2017

1 reference

title

A novel and effective approach to treating rhinitis with nasal antihistamines (English)

1 reference

17 August 2017

1 reference

Michael A Kaliner

1

1 reference

17 August 2017

publication date

1 November 2007

1 reference

Annals of Allergy, Asthma & Immunology

17 August 2017

published in

1 reference

17 August 2017

volume

99

1 reference

17 August 2017

issue

5

1 reference

17 August 2017

page(s)

383-90; quiz 391-2, 418

1 reference

Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Review of azelastine nasal spray in the treatment of allergic and non-allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

A placebo controlled study comparing the efficacy of intranasal azelastine and beclomethasone in the treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960560-1

7 January 2021

10.1016/S1081-1206(10)60560-1

Identifiers

DOI

1 reference

17 August 2017

1 reference